Actuate Therapeutics (ACTU) investor relations material

Executive summary

• Focused on developing elraglusib, a GSK-3β inhibitor, for difficult-to-treat cancers, with both IV and oral formulations advancing in clinical studies.

• Phase 2 data in metastatic pancreatic cancer showed statistically significant survival benefits, supporting further development.

• FDA clearance received for Phase 1/2 study of oral elraglusib; additional pediatric and combination studies planned, pending funding.

Financial highlights

• Net loss for Q2 2026 was $4.87M, improved from $5.95M in Q2 2025; six-month net loss was $10.49M, down from $12.27M year-over-year.

• Operating expenses for Q2 2026 were $4.91M, down from $5.97M in Q2 2025, driven by lower R&D and G&A costs.

• Cash and cash equivalents as of June 30, 2026 were $4.43M, with working capital of $0.94M.

• No revenue generated; accumulated deficit reached $165.1M as of June 30, 2026.

Outlook and guidance

• Current cash is expected to fund operations only through September 2026; additional capital is required to continue development.

• Management anticipates increased R&D and G&A expenses as clinical programs expand, contingent on successful fundraising.

• Substantial doubt exists regarding ability to continue as a going concern without new financing.